DK1981981T3 - Monoklonalt anti-met antistof, fragmenter og vektorer deraf til behandling af tumorer, samt tilsvarende produkter - Google Patents

Monoklonalt anti-met antistof, fragmenter og vektorer deraf til behandling af tumorer, samt tilsvarende produkter

Info

Publication number
DK1981981T3
DK1981981T3 DK07704350.3T DK07704350T DK1981981T3 DK 1981981 T3 DK1981981 T3 DK 1981981T3 DK 07704350 T DK07704350 T DK 07704350T DK 1981981 T3 DK1981981 T3 DK 1981981T3
Authority
DK
Denmark
Prior art keywords
tumors
vectors
treatment
fragments
monoclonal anti
Prior art date
Application number
DK07704350.3T
Other languages
English (en)
Inventor
Paolo Maria Comoglio
Elisa Vigna
Silvia Giordano
Original Assignee
Metheresis Translational Res Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metheresis Translational Res Sa filed Critical Metheresis Translational Res Sa
Application granted granted Critical
Publication of DK1981981T3 publication Critical patent/DK1981981T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
DK07704350.3T 2006-02-06 2007-02-05 Monoklonalt anti-met antistof, fragmenter og vektorer deraf til behandling af tumorer, samt tilsvarende produkter DK1981981T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06101345 2006-02-06
PCT/EP2007/051066 WO2007090807A1 (en) 2006-02-06 2007-02-05 Anti-met monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products

Publications (1)

Publication Number Publication Date
DK1981981T3 true DK1981981T3 (da) 2011-09-26

Family

ID=36616994

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07704350.3T DK1981981T3 (da) 2006-02-06 2007-02-05 Monoklonalt anti-met antistof, fragmenter og vektorer deraf til behandling af tumorer, samt tilsvarende produkter

Country Status (21)

Country Link
US (2) US8388958B2 (da)
EP (2) EP1981981B1 (da)
JP (1) JP5306828B2 (da)
KR (1) KR101429297B1 (da)
CN (1) CN101379192B (da)
AT (1) ATE514715T1 (da)
AU (1) AU2007213804B2 (da)
BR (1) BRPI0707480A8 (da)
CA (1) CA2638889C (da)
CY (1) CY1111884T1 (da)
DK (1) DK1981981T3 (da)
EA (1) EA015580B1 (da)
ES (1) ES2368864T3 (da)
IL (1) IL192879A (da)
MX (1) MX2008009833A (da)
PL (1) PL1981981T3 (da)
PT (1) PT1981981E (da)
SG (2) SG169382A1 (da)
SI (1) SI1981981T1 (da)
WO (1) WO2007090807A1 (da)
ZA (1) ZA200806559B (da)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2014681A1 (en) 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
IL198545A0 (en) * 2008-05-14 2011-07-31 Metheresis Translational Res Sa High affinity binding site of hgfr and methods for identification of antagonists thereof
EP2127683A1 (en) * 2008-05-29 2009-12-02 Metheresis Translational Research SA Anti-Met monoclonal antibody, fragments and derivatives thereof for use in tumor imaging, corresponding compositions and kits
PA8849001A1 (es) 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
EP2287197A1 (en) * 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET antibody and its use for the detection and the diagnosis of cancer
KR101671378B1 (ko) 2009-10-30 2016-11-01 삼성전자 주식회사 ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그의 용도
KR101748707B1 (ko) * 2009-11-27 2017-06-20 삼성전자주식회사 ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그를 이용한 암 진단용 키트
NZ602294A (en) * 2010-03-10 2015-04-24 Genmab As Monoclonal antibodies against c-met
US9175084B2 (en) 2010-04-02 2015-11-03 Fujirebio Inc. Diagnostic marker for effect of anticancer agent
US9169329B2 (en) * 2010-06-01 2015-10-27 Ludwig Institute For Cancer Research Antibodies directed to the receptor tyrosine kinase c-Met
JP5955322B2 (ja) * 2010-09-03 2016-07-20 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 抗ｃ−ｍｅｔ抗体及びその使用方法
AU2011325098B2 (en) 2010-11-03 2016-07-14 Argen-X N.V. c-Met antibody combinations
DK2500036T3 (da) * 2011-03-18 2014-08-04 Metheresis Translational Res Sa MET-hæmmere til øgning af virkningen af radioterapi
CA2843771A1 (en) 2011-09-20 2013-03-28 Eli Lilly And Company Anti-c-met antibodies
EP2773660A2 (en) 2011-11-03 2014-09-10 Argen-X B.V. Chimeric human-camel antigens and their use
US20130129718A1 (en) 2011-11-21 2013-05-23 Genentech, Inc. Purification of anti-c-met antibodies
WO2013079973A1 (en) 2011-12-02 2013-06-06 Di Cara Danielle Marie Antibodies against hgf - receptor and uses
KR101910601B1 (ko) 2011-12-22 2018-10-23 삼성전자주식회사 면역원성이 제거된 항 ｃ-Ｍｅｔ 인간화 항체 및 그의 용도
CN103382223B (zh) * 2012-04-01 2015-06-10 上海益杰生物技术有限公司 针对表皮生长因子受体隐蔽表位和t细胞抗原的多功能抗体多肽
JP6429771B2 (ja) * 2012-06-21 2018-11-28 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ｃ−Ｍｅｔに結合する抗原結合タンパク質
ITTO20130012A1 (it) 2013-01-09 2014-07-10 Metheresis Translational Res S A Nuovi frammenti anticorpali, relative composizioni ed usi
WO2016042412A1 (en) 2014-09-16 2016-03-24 Symphogen A/S Anti-met antibodies and compositions
WO2016149116A1 (en) * 2015-03-13 2016-09-22 University Of Maryland, Baltimore Antibodies targeting s100b and methods of use
US20180057595A1 (en) 2015-03-16 2018-03-01 Celldex Therapeutics, Inc. Anti-MET Antibodies and Methods of Use Thereof
GB201611123D0 (en) * 2016-06-27 2016-08-10 Euremab Srl Anti met antibodiesand uses thereof
IT201800000534A1 (it) * 2018-01-03 2019-07-03 Procedimenti per la promozione della crescita cellulare degli isolotti pancreatici.
CA3036643C (en) 2016-09-29 2021-10-26 Mitsubishi Tanabe Pharma Corporation Cmet monoclonal binding agents, drug conjugates thereof and uses thereof
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
CN106872695B (zh) * 2017-01-20 2019-06-11 中山大学 一种h7亚型禽流感病毒血凝素抗体间接elisa检测试剂盒
IT201800000535A1 (it) * 2018-01-03 2019-07-03 Procedimenti per la cura del cancro.
IT201800003875A1 (it) 2018-03-22 2019-09-22 Metis Prec Medicine Sb S R L Nuova combinazione di agenti terapeutici per il trattamento di un tumore e/o metastasi
MA52238A (fr) * 2018-03-28 2021-02-17 Mitsubishi Tanabe Pharma Corp Conjugués de médicament d'agents de liaison monoclonaux cmet, et utilisations associées
IT201800009282A1 (it) 2018-10-09 2020-04-09 Metis Prec Medicine Sb Srl Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi
EP4031574A1 (en) 2019-09-16 2022-07-27 Regeneron Pharmaceuticals, Inc. Radiolabeled met binding proteins for immuno-pet imaging

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US6814962B1 (en) 1994-06-02 2004-11-09 Aventis Pharma S.A. Recombinant viruses and their use for treatment of atherosclerosis and other forms of coronary artery disease and method, reagent, and kit for evaluating susceptibility to same
US6214344B1 (en) * 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
HN2004000285A (es) * 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET

Also Published As

Publication number Publication date
BRPI0707480A2 (pt) 2011-05-03
US20090285807A1 (en) 2009-11-19
IL192879A (en) 2014-02-27
SG169382A1 (en) 2011-03-30
MX2008009833A (es) 2008-10-23
US20120134996A1 (en) 2012-05-31
CA2638889A1 (en) 2007-08-16
PT1981981E (pt) 2011-10-04
JP5306828B2 (ja) 2013-10-02
IL192879A0 (en) 2009-02-11
AU2007213804A8 (en) 2008-08-28
EA200870234A1 (ru) 2009-02-27
EP2192188A1 (en) 2010-06-02
KR101429297B1 (ko) 2014-08-12
ES2368864T3 (es) 2011-11-23
ATE514715T1 (de) 2011-07-15
KR20090013745A (ko) 2009-02-05
JP2009526010A (ja) 2009-07-16
EA015580B1 (ru) 2011-10-31
CN101379192A (zh) 2009-03-04
PL1981981T3 (pl) 2011-11-30
CY1111884T1 (el) 2015-11-04
SI1981981T1 (sl) 2012-01-31
CN101379192B (zh) 2013-07-31
AU2007213804A1 (en) 2007-08-16
EP1981981B1 (en) 2011-06-29
US8388958B2 (en) 2013-03-05
CA2638889C (en) 2015-06-02
ZA200806559B (en) 2012-12-27
AU2007213804B2 (en) 2012-12-13
BRPI0707480A8 (pt) 2022-11-08
EP1981981A1 (en) 2008-10-22
SG169383A1 (en) 2011-03-30
US8729043B2 (en) 2014-05-20
WO2007090807A1 (en) 2007-08-16

Similar Documents

Publication Publication Date Title
DK1981981T3 (da) Monoklonalt anti-met antistof, fragmenter og vektorer deraf til behandling af tumorer, samt tilsvarende produkter
CY1120267T1 (el) Αντισωματα ανταγωνιστες κατευθυνομενα εναντι πεπτιδιου σχετιζομενου με το γονιδιο καλσιτονινης για την θεραπευτικη αγωγη αθροιστικης κεφαλαλγιας
CY1125027T1 (el) Μονοκλωνικα αντισωματα κατα κλαουδινης-18 για τη θεραπεια του καρκινου
NL301089I2 (nl) imlifidase
CY2017013I2 (el) ΑΝΤΙΣΩΜΑ ΕΝΑΝΤΙΟΝ PDGFR-α ΓΙΑ ΧΡΗΣΗ ΣΤΗΝ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΟΓΚΩΝ
CY1118012T1 (el) Συνθεσεις αναστολεων κινασης και η χρηση αυτων για την αγωγη καρκινου και αλλων νοσηματων σχετικων προς τις κινασες
EA200901313A1 (ru) Ингибиторы тирозинкиназы брутона
CY1115571T1 (el) Νεες ενωσεις και μεθοδοι για θεραπεια
DK2423331T3 (da) Fremgangsmåde til at bestemme reaktivitet af cancer på behandlinger målrettet mod epidermal vækstfaktor-receptor
CY1118797T1 (el) Ανταγωνιστες toll-ωδους υποδοχεα 3
CY1115871T1 (el) Μεθοδοι για την αντιμετωπιση ουρικης αρθριτιδας
EA200970738A1 (ru) Ингибиторы активности akt
NO20092604L (no) VEGF-spesifikke antagonister antistoff eller antigenbindende fragmenter derav for anvendelse i en fremgangsmåte for å redusere eller forhindre forekomst av kreft hos et individ som aldri har hatt klinisk detekterbar kreft, samt anvendelse derav for fremstilling av et medikament.
CY1120772T1 (el) ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ
SG163525A1 (en) Synthetic peptides for use as inhibitors of neurotransmitter secretion and as inducers of muscle relaxation
IL226717A (en) Isolated nucleic acids encoded by anti-beta human antibodies 7
ATE542823T1 (de) 4,5-dihydro-ä1,2,4ütriazoloä4,3-füpteridine als plk1-proteinkinasehemmer zur behandlung proliferativer erkrankungen
DK1869085T3 (da) Hidtil ukendt anti-PLGF-antistof
ATE432281T1 (de) Pyrrolotriazin-kinasehemmer
CY1112288T1 (el) Θεραπεια του καρκινου με αντισωματα κατα της il-1a
SE0301650D0 (sv) Novel compounds
ITTS20050005A1 (it) Procedimento di analisi di stringhe di sicurezza criptate
FI20075258A0 (fi) Menetelmä integriiniinhibiittorirespondereiden seulomiseksi
IT1392027B1 (it) Anticorpo monoclonale e suo uso per la identificazione della isoforma oncofetale della fibronettina (b-fn) a scopo diagnostico o terapeutico.
ATE500220T1 (de) 2-(1h-indolylsulfanyl)benzylamin-derivate zur verwendung als ssri